Review
. 2012 Aug; 26(6):541-7, 550, 552 passim.

Adjuvant endocrine therapy for breast cancer

Ruta D Rao 1 Melody A Cobleigh  
Affiliations
  • PMID: 22870539
  •     19 citations

Abstract

Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor-positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer. For decades, 5 years of tamoxifen has been the standard treatment. For premenopausal women, it remains so, and we await the results of ongoing trials to define the role of ovarian suppression or ablation with endocrine therapy. If a woman becomes postmenopausal during treatment, consideration should be given to extended adjuvant therapy with an aromatase inhibitor (AI) for another 5 years. In postmenopausal women, trials have shown that AIs are more beneficial than tamoxifen in preventing disease recurrence.They have been compared as upfront treatment for 5 years, as sequential therapy after 2 to 3 years of tamoxifen, and as extended treatment for 5 years after 5 years of tamoxifen. Among the questions still being studied are the optimal duration of extended adjuvant therapy with AIs, how one AI performs compared to another, and whether there is a benefit to intermittent extended adjuvant treatment.

Other Links

The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.
Lena Secky, Martin Svoboda, +5 authors, Theresia Thalhammer.
J Drug Deliv, 2013 Mar 12; 2013. PMID: 23476785    Free PMC article.
Pathways to breast cancer recurrence.
Aamir Ahmad.
ISRN Oncol, 2013 Mar 28; 2013. PMID: 23533807    Free PMC article.
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Julie C Friedland, Donald L Smith, +4 authors, David A Proia.
Invest New Drugs, 2013 May 21; 32(1). PMID: 23686707    Free PMC article.
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.
Quan Jiang, Shilong Zheng, Guangdi Wang.
Future Med Chem, 2013 Jun 06; 5(9). PMID: 23734685    Free PMC article.
Review.
Analysis of HOX gene expression patterns in human breast cancer.
Ho Hur, Ji-Yeon Lee, +2 authors, Myoung Hee Kim.
Mol Biotechnol, 2013 Jul 04; 56(1). PMID: 23820980
Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer.
Yan Zhang, Hua Gao, +2 authors, Jihui Jia.
World J Surg Oncol, 2013 Nov 02; 11. PMID: 24175997    Free PMC article.
Physicians' influence on breast cancer patient compliance.
Karel Kostev, Lilia Waehlert, +2 authors, Peyman Hadji.
Ger Med Sci, 2014 Jan 24; 12. PMID: 24454275    Free PMC article.
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
Fabrice Smieliauskas, Chun-Ru Chien, +2 authors, Ya-Chen Tina Shih.
Pharmacoeconomics, 2014 May 14; 32(7). PMID: 24821281
Systematic Review.
Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.
Xin Wang, Xianglin L Du.
Med Oncol, 2015 Apr 04; 32(5). PMID: 25837434
The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.
Binnaz Demirkan.
J Clin Med, 2013 Jan 01; 2(4). PMID: 26237148    Free PMC article.
Review.
Occupational type affects the receipt of breast cancer adjuvant chemotherapy in China.
Zhengzhi Zhu, Qiang Huo, Shengying Wang, Qifeng Yang.
Oncol Lett, 2015 Dec 02; 10(4). PMID: 26622887    Free PMC article.
Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
Kristen J Wells, Tonya M Pan, +12 authors, Gwendolyn P Quinn.
Support Care Cancer, 2016 May 06; 24(10). PMID: 27146492    Free PMC article.
Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
Bobby Daly, Olufunmilayo I Olopade, +3 authors, Dezheng Huo.
JAMA Oncol, 2017 Feb 06; 3(7). PMID: 28152150    Free PMC article.
Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Fabian T Camacho, Xi Tan, +3 authors, Rajesh Balkrishnan.
Medicine (Baltimore), 2017 Jun 15; 96(24). PMID: 28614244    Free PMC article.
A qualitative exploration of race-based differences in social support needs of diverse women with breast cancer on adjuvant therapy.
Andrew J Paladino, Janeane N Anderson, +7 authors, Ilana Graetz.
Psychooncology, 2019 Jan 13; 28(3). PMID: 30636189    Free PMC article.
TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF‑7 cells.
Shuai Zhao, Xiaohua Li, +3 authors, Xun Zhu.
Oncol Rep, 2020 Apr 24; 43(6). PMID: 32323833    Free PMC article.
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Abdulaziz B Hamid, Ruben C Petreaca.
Cancers (Basel), 2020 Apr 15; 12(4). PMID: 32283832    Free PMC article.
Review.
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
Komal Waqas, Joana Lima Ferreira, +3 authors, M C Zillikens.
J Bone Oncol, 2021 May 06; 28. PMID: 33948427    Free PMC article.
Review.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.